Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2016 Jul 1;26(13):3073-3080. doi: 10.1016/j.bmcl.2016.05.005. Epub 2016 May 4.

Discovery of novel 7-azaindoles as PDK1 inhibitors.

Author information

1
Merck KGaA, Biopharma, Global Research & Development, Frankfurter Str. 250, D-64293 Darmstadt, Germany.
2
Organisch-Chemisches Institut, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany.
3
Merck KGaA, Biopharma, Global Research & Development, Frankfurter Str. 250, D-64293 Darmstadt, Germany. Electronic address: ulrich.graedler@merckgroup.com.

Abstract

A combined screening strategy using HTS together with focused kinase library and virtual screening led to the identification of diverse chemical series as PDK1 inhibitors. We focused our medicinal chemistry efforts on 7-azaindoles with low micromolar IC50s (e.g., 16: IC50=1.1μM) in the biochemical PDK1 assay. Our structure-guided optimization efforts considered also PDK1 X-ray structures with weaker binding fragments and resulted in 7-azaindoles with significantly improved biochemical PDK1 potency in the two-digit nanomolar range. However, the most potent analogues only showed moderate activities in a cellular mechanistic assay (42: IC50=2.3μM) together with either low microsomal stability or low permeability. The described structure-activity relationship together with PDK1 X-ray structures and early ADME data provided the basis for our subsequent hit-to-lead program.

KEYWORDS:

Fragment-screening; Kinase inhibitor; PDK1; Protein crystallography; Structure-based design; Virtual screening

PMID:
27217002
DOI:
10.1016/j.bmcl.2016.05.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center